Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells

SERA KAYACAN, KAAN YILANCIOGLU, AYSE SEDA AKDEMIR, FATMA KAYA-DAGISTANLI, GULAY MELIKOGLU and MELEK OZTURK
Anticancer Research March 2021, 41 (3) 1271-1282; DOI: https://doi.org/10.21873/anticanres.14884
SERA KAYACAN
1Department of Medical Biology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAAN YILANCIOGLU
2Department of Chemistry–Biology Engineering, Faculty of Engineering and Natural Sciences, Uskudar University, Istanbul, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AYSE SEDA AKDEMIR
1Department of Medical Biology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FATMA KAYA-DAGISTANLI
1Department of Medical Biology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GULAY MELIKOGLU
3Department of Pharmacognosy, Pharmacy Faculty, Istanbul University, Istanbul, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MELEK OZTURK
1Department of Medical Biology, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mozturk@istanbul.edu.tr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: We aimed to investigate the synergistic effects of apigenin and curcumin on the cross-talk between apoptosis and autophagic cell death, as well as on paraptosis in HeLa cells. Materials and Methods: Cell viability was measured using the MTT assay. Synergistic effects were measured using the Bliss independence model. qRT-PCR was used to study the expression of genes related to apoptosis, autophagic cell death, and cross-talk. GRP78/BiP immunostaining was used to identify endoplasmic reticulum (ER) stress. Results: Treatment with a combination of apigenin and curcumin increased the expression levels of genes related to cell death in HeLa cells 1.29- to 27.6-fold. The combination of curcumin and apigenin showed a synergistic anti-tumor effect via cross-talk between processes leading to apoptosis and autophagic cell death, as well as ER stress-associated paraptosis. GRP78 expression was down-regulated, and massive cytoplasmic vacuolization was observed in HeLa cells. Conclusion: The combination of curcumin and apigenin is an effective potential therapeutic for cervical cancers.

Key Words:
  • Curcumin
  • apigenin
  • synergy
  • autophagic cell death
  • apoptosis
  • paraptosis
  • GRP78
  • HeLa cell

Cancer is a disease caused by the abnormal proliferation and differentiation of cells and is governed by tumorigenic factors (1). Cervical cancer is a major cause of death among young women. There have been significant advances in the diagnosis and treatment of cervical cancer (2). One of the most effective ways of treating cancer is chemotherapy. However, chemotherapy alone may not be adequate for effective treatment due to drug resistance and systemic toxicity. Thus, multiple cytotoxic drugs may need to be used in combination for effective treatment. The combined use of biological agents with cytotoxic features has yielded promising results while lowering their toxic effect on cells, showing the benefits of combination therapy (3, 4). In light of this information, new combination therapies have to be developed for cancer treatment.

Many anti-cancer drugs derived from natural products are widely used in cancer treatment due to their high efficacy and lower toxicity (5). Recent studies have revealed that flavonoids from plant sources can be used as anti-cancer agents. Phenolic compounds, including apigenin and curcumin, are characterized by their broad biological activities, and their benefits have been demonstrated in numerous mammalian systems in vitro and in vivo. Phenolic compounds act as free-radical scavengers and antioxidants, exhibiting anti-mutagenic, anti-inflammatory, antiviral, and anti-tumorigenic effects (6-9).

Apigenin has well-known antioxidant effects, and it can also be used as a therapeutic agent to fight diseases, including autoimmune and neurodegenerative diseases, inflammation, and several types of cancers (10, 11). Apigenin also targets signaling pathways regulating cell cycle and cellular migration. The different mechanisms underlying the potential therapeutic action of apigenin and its anti-cancer, anti-inflammatory, and antioxidant effects have been investigated (12, 13). Apigenin has nutraceutical potential in addition to its many interesting pharmacological activities. As a dietary supplement, apigenin is under investigation for its potential to prevent the recurrence of neoplasias in a phase 2 clinical study that includes patients with colorectal cancer (14). Apigenin’s potential therapeutic action derives from the arrest of the cell cycle at different proliferation stages and induction of apoptosis (12). It has been shown that apigenin has a cytotoxic effect mainly on cancer cells rather than on normal cells and is less toxic compared to other flavonoids (15).

Curcumin, a naturally occurring compound, has been shown to have pleotropic pharmacological properties, including antioxidant, anti-inflammatory, antiviral, and antitumor effects (16-19). Various studies have shown the effective use of curcumin in several types of cancer (18, 19). Curcumin modulates several cellular signaling pathways involved in cell cycle, apoptosis, and cellular differentiation, thus suppressing the proliferation of cancer cells (20, 21). Curcumin may also sensitize tumor cells to targeted therapy agents and reverse resistance to chemotherapeutic drugs (16, 19). In addition to in vitro and in vivo models, the effectiveness of curcumin combination chemotherapy has been reported in several clinical trials (22). The combination of apigenin and curcumin has been shown to effectively reduce tumor activity in various cancers, either when used independently (23-27) or in combination with various chemotherapeutic drugs (28-31). Combined therapeutic strategies involving apigenin or curcumin and other chemotherapeutic drugs have been developed as adjuvant chemotherapy to enhance the anti-cancer effects of these natural compounds on various types of cancers and overcome cancer drug resistance or alleviate other adverse effects of chemotherapy. Apigenin has been shown to reduce the side effects of chemotherapeutic drugs (10, 11), and curcumin reverses resistance to chemotherapeutic drugs (22, 30). Choudhury et al. have shown that the synergistic effect of apigenin and curcumin can induce the death of A549 lung cancer cells (17). They reported that the anticancer activity of these two compounds inhibited microtubule polymerization and triggered apoptosis in cancer cells through this mechanism (17).

One of the first targeted strategies in cancer treatment is blocking cell proliferation and inducing apoptosis. After exposure to anti-tumor agents, cells may undergo apoptosis, autophagic cell death, or necroptosis; these pathways may be activated independently or after cross-talk between relevant signaling pathways, which can be initiated by a common stimulus but with different mechanisms of action (32, 33). Apoptosis can be initiated by either intrinsic or extrinsic cellular triggers. Bcl-2 family members, such as antiapoptotic (including Bcl-2, Bcl-xL, Mcl-1, and Bcl-W) and proapoptotic (including Bax, Bak, Bad, Bid, Bif, Bik, Bcl-xS, and NOXA) proteins, are responsible for the intrinsic pathway, while death receptors (including FAS, TRAILs, and TNFR) play important roles in the extrinsic pathway (33). Apoptosis is a caspase-dependent process that mainly involves Caspase-3, -8 and -9 (33, 34). Autophagy is an important process in balancing cellular survival. A breakdown or increase in autophagic activity may induce cell death. Depending on the conditions, autophagy-related proteins, such as Atg12, Atg5, and Beclin-1 can direct the pathways to cellular death (32, 35). A common stimulus within the same cell can activate apoptotic and autophagy-mediated cell death using different mechanisms (32, 33). Recent studies have shown that cells can choose one of two death pathways by a cross-talk mechanism that uses well-known regulatory genes, such as Bcl-2, Bcl-xL, Atg5, p53, Beclin-1, Bif-1, and BNIP-3 (32, 36). Targeting autophagy-related cell death and/or apoptosis can increase the efficacy of cancer treatment (32).

On the other hand, an alternative, non-apoptotic cell death pathway, such as paraptosis, may be targeted for the development of new therapies. Paraptosis is characterized by extensive cytoplasmic vacuolization due to the dilation of the endoplasmic reticulum (ER) and/or mitochondria (37, 38). Cytoplasmic vacuolization may be preceded by induction of ER stress. The chaperone glucose-regulated protein (GRP78/BiP) is a major regulator of ER stress. GRP78/BiP has critical cytoprotective roles in oncogenesis, and it is often over-expressed in cancer cells (39). Increased expression of GRP78/BiP has been related to drug resistance, high pathological grades, and short survival times in various types of cancers (40).

In this study, our aim was to investigate the synergistic effects of the apigenin, which was isolated from the C. nerimaniae plant, a species endemic to Turkey, and curcumin, on gene expression specifically related to apoptosis and autophagy-related cell death and to determine the potential cross-talk between apoptotic and autophagic cell death mechanisms and ER stress-associated paraptosis in the HeLa cell line.

Materials and Methods

Cell culture. The human cervical cancer cell line (HeLa) was purchased from ATCC (ATCC-CCL-2, Manassas, VI, USA). HeLa cells were grown in Minimum Essential Medium (MEM, Sigma-Aldrich, St. Louis, MO, USA) which contained 10% Fetal Bovine Serum (FBS, Gibco, Thermo Fisher, Waltham, MA, USA) and 100 U/ml penicillin and 50 mg/ml streptomycin. The cells were grown as monolayer in 25 cm2 flasks in a 5% CO2 incubator at 37°C until 80-85% confluency (41). In the study, the cells were divided in in four groups: 1) curcumin alone, 2) apigenin alone, 3) both curcumin and apigenin (combination group) and 4) control group without curcumin and apigenin.

Drugs. Apigenin (4, 5, 7-trihydroxyflavone) was isolated from C. nerimaniae, an endemic plant in Turkey and was characterized following the procedure published elsewhere (42). The extract of dried whole plant was first isolated by petroleum ether and then with 95% ethanol. The concentrated ethanol extract was diluted with distilled H2O and extracted with benzene and chloroform. Apigenin was obtained from the chloroform extract. For the isolation and purification of the apigenin, column chromatography, preparative thin layer chromatography (TLC), and paper chromatography (PC) were performed. The structures of apigenin were determined by comparison with authentic samples (TLC, UV, IR) (42). The stock solution for apigenin was prepared by adding and dissolving crystallized apigenin in 100% dimethyl sulfoxide (DMSO) and the molar extinction coefficient was used to determine the concentration. Curcumin was obtained from Sigma-Aldrich. Final DMSO concentrations were set to be lower than 0.1% (v/v).

MTT proliferation assay. The cell proliferation rates and cytotoxic effects of apigenin and curcumin on Hela cells were determined by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Sigma-Aldrich) and trypan blue. Ninety-six well plates (30×103 cells/well) were used to determine the viability of HeLa cells. MTT assay was performed as previously described (43, 44). The medium was removed as soon as the incubation finished and a total of 40 μl MTT solution which was dissolved in phosphate buffer solution (PBS) (5 mg/ml) was added into each well. After incubating at 37°C for 4 h, 160 μl DMSO was added. After overnight incubation, optical densities of the samples were measured with μQuant Elisa plate reader (Bio-tek Inst, Vinoski, VT, USA) at 570 nm and 690 nm (45). All experiments were repeated three times and the median values were calculated.

Total RNA extraction. For each experimental group, 150×103 cells/ml were seeded in 12 well plates. Following a 24 h incubation at 37°C, trypsin was added into the wells and the cells were re-suspended and centrifuged at 12.000 × g for 2 min and the supernatant was removed. Total RNA was extracted from HeLa cells as described by the manufacturer (Ambion PureLink RNA Mini Kit, Cat. No: 12183-018A, Thermo Fisher Scientific, Austin, TX, USA) and was measured using Qubit (Qubit 2.0 Fluorometer, Invitrogen, Carlsbad, CA, USA). The extracted total RNA was used to synthesize cDNA to determine the expression levels of TRADD, FADD, Bid, Bcl-xL, Fas, TRAF2, TNFR1, TNF, Caspase-3, -8, -9, NOXA, Bad, Bif-1, Atg5, Atg12, DAPk, BNIP-3 and Beclin-1 by quantitative RT-PCR (qRT-PCR) method. All cDNA products were stored at –20°C until experiments.

qRT-PCR experiment. qRT-PCR was used to assess the gene expression profiles of apoptosis and autophagic cell death related genes (46, 47). Eight wells were used for each experimental group. Each reaction consisted of 200 ng total RNA, 10 μl buffer, 1μl enzyme mix, in a total volume of 20 μl (Applied Biosystems, High Capacity RNA-to-cDNA Kit, Cat. No: 4387406, Foster City, CA, USA). The reaction mix was incubated for 60 min at 37°C followed by 5 min at 95°C. The PCR reaction was run in 96 well plates (TaqMan Array 96-Well Fast Plate, Custom Format 48, Applied Biosystems) using a master mix (Applied Biosystem, TaqMan Gene, expression Master Mix, Cat. No: 4369016), nuclease free dH2O, and cDNA with probes and primers in 7500 Fast Real-Time PCR Systems (Applied Biosystems), each well contained a total of 20 μl of reaction mix. Each experiment was repeated three times and the median values were calculated.

The expression levels of apoptotic genes (caspase-3, caspase-8, caspase-9), proapoptotic Bcl-2 member genes of mitochondria related to apoptotic pathway (Bcl-xL, Bid, Bad and NOXA), receptor mediated apoptotic pathway genes (TRADD, FADD, TRAF2, TNF, TNFR1 and Fas), autophagy related cell death genes (Atg5, Atg12, DAPK and Beclin-1), and crosstalk genes related to apoptosis and autophagy (Bif-1 and BNIP-3) were measured by qRT-PCR. The 18S, β-actin and GAPDH were used as reference. Relative mRNA levels were calculated using 2–ΔΔCt method (48).

Determination of synergistic effects. All drug-interaction experiments were performed by a 4×4 checkerboard assay. The cell viabilities in the presence of curcumin (Sigma-Aldrich Company, C1386) (0-100 μM) and apigenin (0-100 μM) were determined by MTT assay. Initial drug concentration was zero (no drug) and the drug doses were gradually increased with 12 different doses (from 0 to 100 μM). In experiments, doses of apigenin and curcumin were adjusted so that as the dose increased cell viability decreased. Cell viability was higher than 50% at lowest dose and lower than 50% at highest dose (49). All interactions and independent effects of the drugs were measured using the Bliss independence model utilizing probabilistic theory using MATLAB (50).

Immunocytochemistry. The Histostain Plus Bulk Kit (Cat no: 85-8943, Invitrogen) was used for immunoperoxidase staining. The HeLa cells were grown in 24-well plates on coverslips then fixed with 4% paraformaldehyde at room temperature (RT) for 15 min. The cells were treated by 3% H2O2 prepared in methanol for 5 min, washed for 5 min in phosphate-buffered-saline (PBS) and then blocked by the blocking solution for 15 min. The coverslips were incubated with an anti-GRP78 (1:100; sc-376768, Santa Cruz, CA, USA) antibody at 4°C overnight, washed with PBS. Specific staining was performed by biotinylated universal secondary antibody, horseradish peroxidase streptavidin complex. The enzyme activity was developed using AEC substrate and then the cells were counterstained with hematoxylin. All procedures except incubation with the primary antibody were applied on the negative control.

Cytological semi-quantitative analysis. Leica DM 2500 light microscope was used for the cytological score analysis, and the samples were photographed with a Leica DFC280 digital camera system (Leica Microsystems, Wetzlar, Germany). Cytological score analysis was performed at a magnification of 400×. Ten different areas from each slide were scored by two researchers in a blinded manner. The intensity of HeLa cell immunostaining was semiquantitatively evaluated using the following categories: 0 (no staining), 1+ (weak, but detectable staining), 2+ (moderate staining), 3+ (distinct staining), and 4+ (intense staining). A histologic score (H score) was derived for each slide by summing the percentage of stained cells at each intensity category and multiplying that value by the weighted intensity of the staining, using the following formula: H Score ΣPi (i + 1) (46).

Statistical analysis. One-way ANOVA test was used to determine the differences between the drug and control groups in terms of time and dose. The differences between drug and control groups in terms of cytotoxicity were determined by Dunnett’s test (p<0.05) (GraphPad Prism v. 4, San Diego, CA, USA).

Results

Cytotoxicity and cell viability assays. Cell proliferation rates and cytotoxicity of apigenin and curcumin in HeLa cells were measured using the MTT assay. The viability graph (%) based on the results is shown in Figure 1. We observed significant differences between the treated and control groups after 24 h (p<0.001). While the cell viability rates for curcumin and apigenin alone were 50.98% and 50.64%, respectively, the combination treatment inhibited cell viability at a rate of 89.26%. Our results showed that the combined use of these drugs induced significant cytotoxicity in the treatment group compared to the control group in a time- and dose-dependent manner. Cell proliferation was significantly inhibited even at the lowest concentrations.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Cell viability of HeLa cells based on drug (apigenin and curcumin) concentrations.

Synergistic effect of curcumin and apigenin on autophagic and apoptotic cell death. We investigated whether the combined use of apigenin and curcumin had a synergistic effect on apoptotic and autophagic cell death in the HeLa cell line. Curcumin or apigenin treatment alone at concentrations of 0.025-0.01 μg/μl did not have any significant effect on cell proliferation (Figure 1). Cell proliferation was reduced after a combination treatment with curcumin and apigenin at concentrations of 0.03, 0.05, and 0.09 μg/μl, and the inhibitory rates were 46.64%, 49.4%, and 38.17%, respectively. While some concentrations of curcumin (0.025 and 0.05 μg/μl) and apigenin (0.03-0.05 μg/μl) showed an antagonistic effect, the combined use of 0.09 μg/μl curcumin and 0.06 μg/μl apigenin showed a synergistic anti-tumor effect (Figure 2).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

The upper left shows the scores using the Bliss independence model of drug-drug interactions for the curcumin-apigenin combination used on the HeLa cell line (negative scores represent stimulated antagonism). The upper right demonstrates the 2D response surface. The lower left and right show the 3D response surfaces of the drug combination. The yellow and reddish areas of the surfaces demonstrate more antagonistic interactions (decreased/lower growth inhibition) compared to the green and blue areas, which represent more additive/synergistic interactions (increased/higher growth inhibition). Lower left and right: The X- and Y-axes show drug concentrations plotted against the percentage difference of observed and model-predicted growth inhibition of the HeLa cells at different concentrations of drug combinations.

mRNA expression analysis. We studied the expression levels of genes related to receptor-mediated and mitochondria-related apoptotic pathways, autophagy, and the cross-talk between autophagy and apoptosis using qRT-PCR. Our data revealed that treatment with the combination of curcumin and apigenin increased the expression levels of the genes studied compared to the control group. The levels of transcriptional activation ranged from 1.29-fold to 27.6-fold. As shown in Figure 3, we detected an increase in the expression levels of Caspase-8 (19.8-fold) and Caspase-9 (7.38-fold), while the levels of Caspase-3 expression decreased by 0.69 compared to the control. Bad (5.73-fold) and Bid (3.63-fold) gene expression was increased in the drug combination group, while the increase in the expression levels of NOXA was smaller (1.29-fold). We also observed significant differences in the expression levels of genes related to the TRADD receptor-mediated apoptotic pathway. As shown in Figure 3, the expression of TNFR1 (11.45-fold), FADD (6.94-fold), and TRADD (4.34-fold) genes was increased in the drug combination group. TNF (27.6-fold), FAS (8.41-fold), and TRAF2 (6.92-fold) showed the higher increases. Among genes related to autophagic cell death, Atg12 (12.71-fold), DAPK (10.89-fold), Atg5 (6.02-fold), and Beclin-1 (4.81-fold) were highly expressed in the drug combination group compared to the control group. Expression levels of genes related to cross-talk, such as Bif-1 (12.23-fold), BNIP-3 (11.61-fold), and Bcl-xL (6.8-fold) were increased in HeLa cells in the drug combination group compared to the control group (Figure 3).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Changes in the expression levels of apoptotic genes (Caspase-3, Caspase-8, Caspase-9, FAS, TNF, TNFR1, FADD, TRAF2, TRADD, NOXA, Bad, Bcl-xL, and Bid), autophagy-related cell death genes (Atg12, Atg5, Beclin-1, and DAPK) and genes related to the cross-talk between apoptotic and autophagy-related cell death (Bif-1 and BNIP-3) after the combined drug treatment.

In the apigenin-only group, expression levels of Caspase-9 (40.64-fold), Bad (17.44-fold), and TRAF2 (1.12-fold) were significantly increased compared to the control group. On the other hand, expression levels of Caspase-3 (0.13-fold), Caspase-8 (0.17-fold), Bid (0.27-fold), FADD (0.28-fold), FAS (0.52-fold), TNF (0.26-fold), and TRADD (0.09-fold) were significantly lower than those of other apoptotic genes. Expression levels of autophagy-related cell death genes, such as Atg12 (0.08-fold), Atg5 (0.4-fold), Beclin-1 (0.07-fold), Bcl2-xL (0.12-fold), and DAPK1 (0.2-fold) were also significantly decreased. After apigenin-only treatment, BNIP3 and Bif1 gene expression was not detected.

In the curcumin-only group, the expression levels of genes related to apoptosis, such as Caspase-9 (273.86-fold), Caspase-3 (2.05-fold), Caspase-8 (1.84-fold), and the Bcl-2 family members, Bad (21.48-fold), Bid (2.27-fold) and NOXA (4.4-fold) were increased. The expression levels of apoptosis receptor-mediated pathway genes, such as TNF (4.28-fold), FADD (2.08-fold), FAS (4.85-fold), and TRAF2 (1.74-fold) were also increased, while TRADD gene expression (0.53-fold) was lower compared to other genes. The expression levels of autophagy-related genes, such as Atg12 (4.65-fold), Atg5 (1.31-fold), Beclin-1 (1.53-fold), and DAPK1 (3.02-fold) were increased. The expression levels of cross-talk genes, including BNIP3 (2.44-fold) and Bif1 (4.6-fold) were increased.

Immunocytochemistry. The expression levels of GRP78/BiP were determined by immunostaining (Figure 4). The intensity of GRP78/BiP immunostaining in the curcumin- or apigenin-only groups was decreased in HeLa cells compared to the control group. In the drug combination group, the immunostaining density of GRP78/BiP was markedly lower than that in the other groups. The combination of apigenin and curcumin resulted in the down-regulation of GRP78/BiP expression. We observed cytoplasmic vacuolization in cells in all drug-treated groups. In the drug combination groups, the cytoplasm of the cells was almost completely occupied by vacuoles of various sizes (Figure 4).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Immunocytochemistry for GRP78/BiP. Expression levels of GRP78/BiP according to the H-score (E) were markedly decreased in the curcumin and apigenin combination group in contrast to the control group (A) and the other drug-treated groups (B, C) (**p<0.01, ***p<0.00). Extensive cytoplasmic vacuolization (arrows) was observed in HeLa cells in the combination group (D). (A: Control, B: Apigenin, C: Curcumin, D: Curcumin and Apigenin combination groups).

Discussion

Drug combination therapeutic strategies enhance the anti-cancer effects of drugs on various cancers, overcoming cancer drug resistance or reducing the adverse effects of chemotherapy. The combined use of drugs generally reduces toxicity and increases treatment efficacy. It also enables physicians to use low doses of drugs (6, 28, 49). Apigenin and curcumin are natural phenolics with strong anti-cancer effects that use different molecular mechanisms and have low toxicity to normal tissues (11, 51). Previous studies have shown that the use of apigenin in combination with other drugs significantly increases the anti-cancer efficacy of chemotherapeutics in various cancer types by targeting multiple signaling pathways (10, 28, 52). Curcumin also has a potential cytotoxic effect on several cancer types through the induction of apoptosis and cell cycle arrest regulated by the p53 signaling pathway (18, 19, 53). Several clinical trials have reported the combined use of curcumin with docetaxel or doxorubicin during chemotherapy, in which curcumin increased the other drug’s efficacy (22, 54, 55). Apigenin or curcumin have been used as anti-cancer agents with other chemotherapeutic drugs in various types of cancers (10, 19). However, there is only one study that has focused on the synergistic effect of apigenin and curcumin on lung cancer cells resulting in cell death (17). Choudhury et al. have shown that a combination of apigenin and curcumin triggers apoptosis by inhibiting microtubule polymerization and by blocking cell cycle progression in A549 lung cancer cells (17). To our knowledge, no previous study has focused on the synergistic effects of the combined use of apigenin and curcumin on regulatory genes of apoptosis- and/or autophagy-related cell death, as well as on paraptosis-like type of cell death.

In our previous, preliminary study, we observed that treatment with either 0.05 μg/μl of curcumin or 0.05 μg/μl of apigenin induced apoptosis (via Caspase-3, FAS, and TNF) and autophagy-related cell death (via Atg5 and Beclin-1) (56). In the present study, we aimed to evaluate the efficacy and synergistic effect of the combination of curcumin and apigenin on genes that regulate apoptotic and/or autophagy-related cell death in HeLa cells. In order to identify the molecular targets of curcumin and apigenin, the expression of the following genes was analyzed: Bif, Beclin-1, and BNIP-3 (for cross-talk between apoptotic and autophagic cell death); Atg12, Atg5, and DAPK (for autophagic cell death); and Bcl-xL, Bad, Bid, NOXA, FAS, TNFR1, and the Caspases 3, 8, and 9 (for apoptotic cell death). In this study, curcumin (0.01-0.5 μg/μl) or apigenin (0.01-0.5 μg/μl) independently reduced the viability of HeLa cells in a dose-dependent manner, while the combined use of apigenin and curcumin showed a greater synergistic inhibitory effect on cell viability (0.09 μg/μl of curcumin and 0.06 μg/μl of apigenin). Our results showed that a combination of low doses triggered the expression of genes involved in both apoptosis and autophagy-related cell death.

Paraptosis, an alternative, caspase-independent, non-apoptotic cell death mechanism, has been discovered in recent years. It is characterized by massive cytoplasmic vacuolization due to swelling of the ER and mitochondria (37, 38). It has been shown that the ER stress marker, expression of the unfolded protein response regulator GRP78/Bip, is increased during paraptosis of cancer cells (39). GRP78/BiP expression is increased in many cancer types. GRP78/BiP expression can be related to increased tumor aggressiveness and poor prognosis (40). GRP78/BiP down-regulation results in sensitization of cancer cells to drug-induced apoptosis (57). In our study, the combination of curcumin and apigenin induced GRP78/BiP down-regulation and produced extensive cytoplasmic vacuolization, similar to paraptosis-like cell death.

Many studies have reported that targeting apoptosis and/or autophagy-related cell death yields successful results in cancer treatment. As a response to therapeutic agents, cancer cells may undergo apoptosis, necroptosis, or autophagy-related cell death. These pathways have a common initiation mechanism; however, the pathways themselves are different (32, 36). Caspases play a major role in triggering apoptosis, either via mitochondrial or intrinsic pathways, resulting in activation of Caspase-3 and Caspase-9 (33). In this study, we showed that the use of curcumin in combination with apigenin increased Caspase-8 and Caspase-9 gene expression; however, Caspase-3 expression was lower than when either curcumin or apigenin alone were applied. Depending on the complex interactions between cellular proteins, apoptosis can be initiated by different pathways, which are either caspase-dependent or -independent (58, 59). Caspase-3 also has a role in tissue regeneration and cell proliferation in neighboring non-apoptotic cells (34, 60). Overexpression of Caspase-3 has also been reported in a variety of cancer types, which suggests possible crucial roles in oncogenic transformation (60, 61). Flanagan et al. have shown that low levels of Caspase-3 predict a favorable response to 5-fluorouracil (5-FU) based chemotherapy in advanced colorectal cancer cases; thus, they have suggested that Caspase-3 inhibition might be used as a therapeutic approach (62). In this study, apigenin from an endemic plant may have down-regulated Caspase-3 expression by interacting with curcumin in an unknown way. This is the first study showing that an antioxidant, such as apigenin or curcumin, reduces Caspase-3 gene expression. The cytoplasmic vacuolization in the absence of caspase activation is a characteristic of paraptosis. However, it has been suggested that Caspase-9 can induce non-apoptotic cell death, including paraptosis. Paraptosis requires Caspase-9 in the absence of cytochrome C and lacks apoptotic bodies (63). Curcumin has been shown to induce cytoplasmic vacuolization-mediated cell death and paraptosis in malignant breast cancer (64) and glioblastoma (65) cell lines. We observed a higher expression of Caspase-9 in the curcumin-only treatment group, while in the combination group expression was down-regulated. When apigenin was used together with curcumin, the toxicity of curcumin was reduced. We showed that the synergistic effects of these drugs affected different cell death modalities, such as apoptosis, autophagy, and paraptosis-like cell death.

It has been shown that BNIP-3 activates caspase-independent apoptosis, known as the AIF-EndoG pathway (33). Activation of BNIP-3 induces the release of AIF and EndoG from mitochondria, and these molecules translocate to the nucleus to initiate apoptosis (59). We considered that a high level of expression of BNIP-3 (an 11.61-fold increase) might have activated the caspase-independent pathway, resulting in the lower expression of Caspase-3. Meanwhile, apigenin alone decreased the expression levels of genes related to apoptosis, such as Caspase-8, Caspase-3, and other genes related to the apoptotic cell death pathway, indicating that the effect of these molecules on apoptosis was lower than that of the combination group. In the combination group, apigenin+curcumin may have the opposite effect on Caspase-3 expression. It has been suggested that the efficacy of chemotherapeutic agents can be improved by inhibiting the activity of caspases in some cancer cells (59, 66). The limitation of the current study is that protein levels of the expressed genes were not examined; further study is required to examine the expression levels of the Caspase-3 protein.

In this study, we showed that combination treatment induced the expression of proapoptotic genes of the Bcl-2 family, including Bad (5.73-fold), Bid (3.63-fold), and NOXA (1.29-fold) in mitochondrial-mediated pathways. Moreover, the expression of receptor-mediated apoptotic genes, such as TNFR1, FAS, FADD, TRAF2, and TRADD increased between 4.34- and 11.45-fold; the most remarkable increase in gene expression was observed for TNF, with a 27.6-fold increase after the combination treatment. These results suggest that the synergistic effect of curcumin and apigenin together triggered apoptosis by affecting the death receptor-mediated pathway. A number of studies have also emphasized that combined treatment with curcumin can induce apoptosis in cancer cell lines (54, 55). As previously reported, autophagy-related cell death may also be simultaneously induced by extrinsic apoptotic pathway components, including FAS, FADD, TRADD, and TNF (67). Autophagy or apoptosis can promote cell death by acting in sequence or in parallel (68, 69). These two processes share common signaling pathways; only a specific stimulus decides which pathway will be triggered. Recent studies have shown that Atg5, Atg12, Beclin-1, Bcl-xL, Bif-1, and BNIP-3 can mediate the cross-talk between apoptotic and autophagic cell death mechanisms (35, 70-74). Atg5 induces autophagy via cytoprotective and proapoptotic mechanisms, suggesting an effective role in the cross-talk between the two cell death mechanisms. Atg5 knockdown has been shown to inhibit autophagy, triggering apoptosis, and overexpression of Atg5 can sensitize cells to apoptotic stimuli (75). Beclin-1 is a major player in autophagosome formation and functions in the cross-talk with autophagy and apoptotic pathways (35). In addition, DAPK can interact with many proteins with death domains, including Beclin-1, ERK, and TNFR-1, suggesting that protein interaction may increase its expression levels (72).

In this study, we found that the expression of genes related to autophagic cell death – Atg12 (12.71-fold), DAPK (10.89-fold), Atg5 (6.02-fold), Beclin-1 (4.81-fold), and Bcl-xL (6.8-fold) – significantly increased after combination treatment. Bcl-xL is an important anti-apoptotic factor, inhibiting Beclin-1-mediated autophagy. In addition, Beclin-1 and Bcl-xL can cooperate with Atg5 and regulate both autophagy and apoptosis. Thus, Bcl-xL represents a molecular link between autophagy and apoptosis (74, 76). Once Beclin-1 is cleaved by Caspase-8 and is inactivated, it induces autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria (77). In our study, the increase in Beclin-1, Bcl-xL, and Caspase-8 expression after combination treatment supported a synergistic effect and the cross-talk between apoptosis and autophagic cell death.

Our study showed that the expression of Bif-1 and BNIP-3, genes involved in the cross-talk between apoptosis and autophagy-related cell death, increased 12.23- and 11.61-fold, respectively. Bif-1 is important in the mitochondrial pathway of apoptosis, as it interacts with Bax and Bak. Bif-1 can regulate autophagy and suppress tumorigenesis by interacting with Beclin-1. Loss of Bif-1 suppresses autophagosome formation, which triggers tumor development in mice (70). A possible interaction with other genes functioning in autophagy and apoptosis increase the expression of Bif-1 and BNIP-3, suggesting that apoptosis and autophagy are triggered simultaneously (78, 79). It has been reported that autophagy can be induced by proapoptotic BH3-only proteins, such as NOXA and BNIP-3 (79). Our data demonstrates that co-treatment with curcumin and apigenin increased the expression of the proapoptotic genes BNIP-3 (11.61-fold) and NOXA (1.29-fold) in the HeLa cell line. This is the first study showing significantly increased levels of BNIP-3 and Bif-1 in the HeLa cell line, so we suggest that the synergistic effect of apigenin and curcumin induces the cross-talk between autophagy-related cell death and apoptosis. Indeed, the complex mechanisms regulating autophagy, apoptosis, and paraptosis have not been fully revealed. In order to clarify the mechanisms of the cross-talk between these cell death modalities, further studies must be conducted.

Conclusion

In conclusion, our data showed that co-treatment with apigenin and curcumin has significant and synergistic effects on the inhibition of cellular growth in HeLa cells by triggering autophagy-related cell death, apoptosis, and paraptosis-like cell death, and inducing cross-talk between these pathways. We suggest that curcumin may have a remarkable anti-cancer effect due to its low toxicity and has a therapeutic potential when used in combination with apigenin in cervical cancer.

Footnotes

  • ↵* These Authors contributed equally to this study.

  • Authors’ Contributions

    SK, KY and MO designed the study and the concept; SK, KY and ASA performed experiments; SK, KY and MO performed data analysis and wrote the manuscript. SK, KY, ASA, FKD, GM, MO reviewed the data, made adjustments for the study protocols. All Authors read and approved the final version of the manuscript.

  • Conflicts of Interest

    The Authors report no conflicts of interest in relation to this study.

  • Received January 20, 2021.
  • Revision received January 30, 2021.
  • Accepted February 1, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Hanahan D and
    2. Weinberg RA
    : Hallmarks of cancer: the next generation. Cell 144(5): 646-674, 2011. PMID: 21376230. DOI: 10.1016/j.cell.2011.02.013
    OpenUrlCrossRefPubMed
  2. ↵
    1. Šarenac T and
    2. Mikov M
    : Cervical cancer, different treatments and importance of bile acids as therapeutic agents in this disease. Front Pharmacol 10: 484, 2019. PMID: 31214018. DOI: 10.3389/fphar.2019.00484
    OpenUrlCrossRefPubMed
  3. ↵
    1. Srivastava NS and
    2. Srivastava RAK
    : Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signaling and apoptotic pathways in A375 cells. Phytomedicine 52: 117-128, 2019. PMID: 30599890. DOI: 10.1016/j.phymed.2018.09.224
    OpenUrlCrossRefPubMed
  4. ↵
    1. Feng LX,
    2. Li M,
    3. Liu YJ,
    4. Yang SM and
    5. Zhang N
    : Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel. Int J Mol Sci 15(3): 4201-4220, 2014. PMID: 24619193. DOI: 10.3390/ijms15034201
    OpenUrlCrossRefPubMed
  5. ↵
    1. Newman DJ and
    2. Cragg GM
    : Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75(3): 311-335, 2012. PMID: 22316239. DOI: 10.1021/np200906s
    OpenUrlCrossRefPubMed
  6. ↵
    1. Batra H,
    2. Pawar S and
    3. Bahl D
    : Curcumin in combination with anti-cancer drugs: A nanomedicine review. Pharmacol Res 139: 91-105, 2019. PMID: 30408575. DOI: 10.1016/j.phrs.2018.11.005
    OpenUrlCrossRefPubMed
    1. Shukla S and
    2. Gupta S
    : Apigenin: a promising molecule for cancer prevention. Pharm Res 27(6): 962-978, 2010. PMID: 20306120. DOI: 10.1007/s11095-010-0089-7
    OpenUrlCrossRefPubMed
    1. Abotaleb M,
    2. Samuel SM,
    3. Varghese E,
    4. Varghese S,
    5. Kubatka P,
    6. Liskova A and
    7. Büsselberg D
    : Flavonoids in cancer and apoptosis. cancers (Basel) 11(1): 28, 2018. PMID: 30597838. DOI: 10.3390/cancers11010028
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kopustinskiene DM,
    2. Jakstas V,
    3. Savickas A and
    4. Bernatoniene J
    : Flavonoids as anticancer agents. Nutrients 12(2): 457, 2020. PMID: 32059369. DOI: 10.3390/nu12020457
    OpenUrlCrossRefPubMed
  8. ↵
    1. Madunić J,
    2. Madunić IV,
    3. Gajski G,
    4. Popić J and
    5. Garaj-Vrhovac V
    : Apigenin: A dietary flavonoid with diverse anticancer properties. Cancer Lett 413: 11-22, 2018. PMID: 29097249. DOI: 10.1016/j.canlet.2017.10.041
    OpenUrlCrossRefPubMed
  9. ↵
    1. Yan X,
    2. Qi M,
    3. Li P,
    4. Zhan Y and
    5. Shao H
    : Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. Cell Biosci 7: 50, 2017. PMID: 29034071. DOI: 10.1186/s13578-017-0179-x
    OpenUrlCrossRefPubMed
  10. ↵
    1. Sung B,
    2. Chung HY and
    3. Kim ND
    : Role of apigenin in cancer prevention via the induction of apoptosis and autophagy. J Cancer Prev 21(4): 216-226, 2016. PMID: 28053955. DOI: 10.15430/JCP.2016.21.4.216
    OpenUrlCrossRefPubMed
  11. ↵
    1. Salmani JMM,
    2. Zhang XP,
    3. Jacob JA and
    4. Chen BA
    : Apigenin’s anticancer properties and molecular mechanisms of action: Recent advances and future prospectives. Chin J Nat Med 15(5): 321-329, 2017. PMID: 28558867. DOI: 10.1016/S1875-5364(17)30052-3
    OpenUrlCrossRefPubMed
  12. ↵
    1. National Library of Medicine
    . Dietary bioflavonoid supplementation for the prevention of neoplasia. Available at: https://clinicaltrials.gov/ct2/show/NCT00609310 [Last accessed on September 12, 2020]
  13. ↵
    1. Salehi B,
    2. Venditti A,
    3. Sharifi-Rad M,
    4. Kręgiel D,
    5. Sharifi-Rad J,
    6. Durazzo A,
    7. Lucarini M,
    8. Santini A,
    9. Souto EB,
    10. Novellino E,
    11. Antolak H,
    12. Azzini E,
    13. Setzer WN and
    14. Martins N
    : The therapeutic potential of apigenin. Int J Mol Sci 20(6): 1305, 2019. PMID: 30875872. DOI: 10.3390/ijms20061305
    OpenUrlCrossRefPubMed
  14. ↵
    1. Bachmeier BE,
    2. Killian PH and
    3. Melchart D
    : The role of curcumin in prevention and management of metastatic disease. Int J Mol Sci 19(6): 1716, 2018. PMID: 29890744. DOI: 10.3390/ijms19061716
    OpenUrlCrossRefPubMed
  15. ↵
    1. Choudhury D,
    2. Ganguli A,
    3. Dastidar DG,
    4. Acharya BR,
    5. Das A and
    6. Chakrabarti G
    : Apigenin shows synergistic anticancer activity with curcumin by binding at different sites of tubulin. Biochimie 95(6): 1297-1309, 2013. PMID: 23485682. DOI: 10.1016/j.biochi.2013.02.010
    OpenUrlCrossRefPubMed
  16. ↵
    1. Yang J,
    2. Cao Y,
    3. Sun J and
    4. Zhang Y
    : Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol 27(4): 1114-1118, 2010. PMID: 19908170. DOI: 10.1007/s12032-009-9344-3
    OpenUrlCrossRefPubMed
  17. ↵
    1. Wang M,
    2. Jiang S,
    3. Zhou L,
    4. Yu F,
    5. Ding H,
    6. Li P,
    7. Zhou M and
    8. Wang K
    : Potential mechanisms of action of curcumin for cancer prevention: focus on cellular signaling pathways and miRNAs. Int J Biol Sci 15(6): 1200-1214, 2019. PMID: 31223280. DOI: 10.7150/ijbs.33710
    OpenUrlCrossRefPubMed
  18. ↵
    1. Ravindran J,
    2. Prasad S and
    3. Aggarwal BB
    : Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11(3): 495-510, 2009. PMID: 19590964. DOI: 10.1208/s12248-009-9128-x
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hu S,
    2. Xu Y,
    3. Meng L,
    4. Huang L and
    5. Sun H
    : Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells. Exp Ther Med 16(2): 1266-1272, 2018. PMID: 30116377. DOI: 10.3892/etm.2018.6345
    OpenUrlCrossRefPubMed
  20. ↵
    1. Tan BL and
    2. Norhaizan ME
    : Curcumin combination chemotherapy: The implication and efficacy in cancer. Molecules 24(14): 2019. PMID: 31295906. DOI: 10.3390/molecules24142527
    OpenUrlCrossRef
  21. ↵
    1. Xu M,
    2. Wang S,
    3. Song YU,
    4. Yao J,
    5. Huang K and
    6. Zhu X
    : Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway. Oncol Lett 11(5): 3075-3080, 2016. PMID: 27123066. DOI: 10.3892/ol.2016.4331
    OpenUrlCrossRefPubMed
    1. Cao X,
    2. Liu B,
    3. Cao W,
    4. Zhang W,
    5. Zhang F,
    6. Zhao H,
    7. Meng R,
    8. Zhang L,
    9. Niu R,
    10. Hao X and
    11. Zhang B
    : Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells. Chin J Cancer Res 25(2): 212-222, 2013. PMID: 23592903. DOI: 10.3978/j.issn.1000-9604.2013.04.01
    OpenUrlCrossRefPubMed
    1. Shukla S,
    2. Fu P and
    3. Gupta S
    : Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer. Apoptosis 19(5): 883-894, 2014. PMID: 24563225. DOI: 10.1007/s10495-014-0971-6
    OpenUrlCrossRefPubMed
    1. Chen B,
    2. Zhang Y,
    3. Wang Y,
    4. Rao J,
    5. Jiang X and
    6. Xu Z
    : Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression. J Steroid Biochem Mol Biol 143: 11-18, 2014. PMID: 24486718. DOI: 10.1016/j.jsbmb.2014.01.009
    OpenUrlCrossRefPubMed
  22. ↵
    1. Sun XD,
    2. Liu XE and
    3. Huang DS
    : Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol Med Rep 6(6): 1267-1270, 2012. PMID: 23023821. DOI: 10.3892/mmr.2012.1103
    OpenUrlCrossRefPubMed
  23. ↵
    1. Liu R,
    2. Ji P,
    3. Liu B,
    4. Qiao H,
    5. Wang X,
    6. Zhou L,
    7. Deng T and
    8. Ba Y
    : Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis. Oncol Lett 13(2): 1024-1030, 2017. PMID: 28356995. DOI: 10.3892/ol.2016.5495
    OpenUrlCrossRefPubMed
    1. Mahbub AA,
    2. Le Maitre CL,
    3. Haywood-Small SL,
    4. Cross NA and
    5. Jordan-Mahy N
    : Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines. Cell Death Discov 1: 15043, 2015. PMID: 27551472. DOI: 10.1038/cddiscovery.2015.43
    OpenUrlCrossRefPubMed
  24. ↵
    1. Banerjee S,
    2. Singh SK,
    3. Chowdhury I,
    4. Lillard JW Jr. and
    5. Singh R
    : Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed) 9: 235-245, 2017. PMID: 28199187. DOI: 10.2741/e798
    OpenUrlCrossRefPubMed
  25. ↵
    1. Zhang HH,
    2. Zhang Y,
    3. Cheng YN,
    4. Gong FL,
    5. Cao ZQ,
    6. Yu LG and
    7. Guo XL
    : Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Mol Carcinog 57(1): 44-56, 2018. PMID: 28833603. DOI: 10.1002/mc.22718
    OpenUrlCrossRefPubMed
  26. ↵
    1. Nikoletopoulou V,
    2. Markaki M,
    3. Palikaras K and
    4. Tavernarakis N
    : Crosstalk between apoptosis, necrosis and autophagy. Biochim Biophys Acta 1833(12): 3448-3459, 2013. PMID: 23770045. DOI: 10.1016/j.bbamcr.2013.06.001
    OpenUrlCrossRefPubMed
  27. ↵
    1. Galluzzi L,
    2. Vitale I,
    3. Aaronson SA,
    4. Abrams JM,
    5. Adam D,
    6. Agostinis P,
    7. Alnemri ES,
    8. Altucci L,
    9. Amelio I,
    10. Andrews DW,
    11. Annicchiarico-Petruzzelli M,
    12. Antonov AV,
    13. Arama E,
    14. Baehrecke EH,
    15. Barlev NA,
    16. Bazan NG,
    17. Bernassola F,
    18. Bertrand MJM,
    19. Bianchi K,
    20. Blagosklonny MV,
    21. Blomgren K,
    22. Borner C,
    23. Boya P,
    24. Brenner C,
    25. Campanella M,
    26. Candi E,
    27. Carmona-Gutierrez D,
    28. Cecconi F,
    29. Chan FK,
    30. Chandel NS,
    31. Cheng EH,
    32. Chipuk JE,
    33. Cidlowski JA,
    34. Ciechanover A,
    35. Cohen GM,
    36. Conrad M,
    37. Cubillos-Ruiz JR,
    38. Czabotar PE,
    39. D’Angiolella V,
    40. Dawson TM,
    41. Dawson VL,
    42. De Laurenzi V,
    43. De Maria R,
    44. Debatin KM,
    45. DeBerardinis RJ,
    46. Deshmukh M,
    47. Di Daniele N,
    48. Di Virgilio F,
    49. Dixit VM,
    50. Dixon SJ,
    51. Duckett CS,
    52. Dynlacht BD,
    53. El-Deiry WS,
    54. Elrod JW,
    55. Fimia GM,
    56. Fulda S,
    57. García-Sáez AJ,
    58. Garg AD,
    59. Garrido C,
    60. Gavathiotis E,
    61. Golstein P,
    62. Gottlieb E,
    63. Green DR,
    64. Greene LA,
    65. Gronemeyer H,
    66. Gross A,
    67. Hajnoczky G,
    68. Hardwick JM,
    69. Harris IS,
    70. Hengartner MO,
    71. Hetz C,
    72. Ichijo H,
    73. Jäättelä M,
    74. Joseph B,
    75. Jost PJ,
    76. Juin PP,
    77. Kaiser WJ,
    78. Karin M,
    79. Kaufmann T,
    80. Kepp O,
    81. Kimchi A,
    82. Kitsis RN,
    83. Klionsky DJ,
    84. Knight RA,
    85. Kumar S,
    86. Lee SW,
    87. Lemasters JJ,
    88. Levine B,
    89. Linkermann A,
    90. Lipton SA,
    91. Lockshin RA,
    92. López-Otín C,
    93. Lowe SW,
    94. Luedde T,
    95. Lugli E,
    96. MacFarlane M,
    97. Madeo F,
    98. Malewicz M,
    99. Malorni W,
    100. Manic G,
    101. Marine JC,
    102. Martin SJ,
    103. Martinou JC,
    104. Medema JP,
    105. Mehlen P,
    106. Meier P,
    107. Melino S,
    108. Miao EA,
    109. Molkentin JD,
    110. Moll UM,
    111. Muñoz-Pinedo C,
    112. Nagata S,
    113. Nuñez G,
    114. Oberst A,
    115. Oren M,
    116. Overholtzer M,
    117. Pagano M,
    118. Panaretakis T,
    119. Pasparakis M,
    120. Penninger JM,
    121. Pereira DM,
    122. Pervaiz S,
    123. Peter ME,
    124. Piacentini M,
    125. Pinton P,
    126. Prehn JHM,
    127. Puthalakath H,
    128. Rabinovich GA,
    129. Rehm M,
    130. Rizzuto R,
    131. Rodrigues CMP,
    132. Rubinsztein DC,
    133. Rudel T,
    134. Ryan KM,
    135. Sayan E,
    136. Scorrano L,
    137. Shao F,
    138. Shi Y,
    139. Silke J,
    140. Simon HU,
    141. Sistigu A,
    142. Stockwell BR,
    143. Strasser A,
    144. Szabadkai G,
    145. Tait SWG,
    146. Tang D,
    147. Tavernarakis N,
    148. Thorburn A,
    149. Tsujimoto Y,
    150. Turk B,
    151. Vanden Berghe T,
    152. Vandenabeele P,
    153. Vander Heiden MG,
    154. Villunger A,
    155. Virgin HW,
    156. Vousden KH,
    157. Vucic D,
    158. Wagner EF,
    159. Walczak H,
    160. Wallach D,
    161. Wang Y,
    162. Wells JA,
    163. Wood W,
    164. Yuan J,
    165. Zakeri Z,
    166. Zhivotovsky B,
    167. Zitvogel L,
    168. Melino G and
    169. Kroemer G
    : Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3): 486-541, 2018. PMID: 29362479. DOI: 10.1038/s41418-017-0012-4
    OpenUrlCrossRefPubMed
  28. ↵
    1. Julien O and
    2. Wells JA
    : Caspases and their substrates. Cell Death Differ 24(8): 1380-1389, 2017. PMID: 28498362. DOI: 10.1038/cdd.2017.44
    OpenUrlCrossRefPubMed
  29. ↵
    1. Kusama Y,
    2. Sato K,
    3. Kimura N,
    4. Mitamura J,
    5. Ohdaira H and
    6. Yoshida K
    : Comprehensive analysis of expression pattern and promoter regulation of human autophagy-related genes. Apoptosis 14: 1165-1175, 2019. DOI:10.1007/s10495-009-0390-2
    OpenUrlCrossRef
  30. ↵
    1. Dagistanli FK,
    2. Ozkaya HM,
    3. Kucukyoruk B,
    4. Biceroglu H,
    5. Metin D,
    6. Gazioglu N,
    7. Oz B,
    8. Kadioglu P and
    9. Ozturk M
    : Preoperative somatostatin analogue treatment might trigger apoptosis and autophagy in tumor tissues of patients with acromegaly: a pilot study. Exp Clin Endocrinol Diabetes 126(3): 168-175, 2018. PMID: 27322826. DOI: 10.1055/s-0042-107243
    OpenUrlCrossRefPubMed
  31. ↵
    1. Vetrivel P,
    2. Kim SM,
    3. Saralamma VVG,
    4. Ha SE,
    5. Kim EH,
    6. Min TS and
    7. Kim GS
    : Function of flavonoids on different types of programmed cell death and its mechanism: a review. J Biomed Res 33(6): 363-370, 2019. DOI: 10.7555/JBR.33.20180126
    OpenUrlCrossRef
  32. ↵
    1. Radosevich JA
    1. Khalili M and
    2. Radosevich JA
    : Paraptosis. In: Apoptosis and beyond: The many ways cells die. Radosevich JA (eds.). Hoboken, NJ, USA: John Wiley & Sons, Inc., pp 343-366, 2018.
  33. ↵
    1. Luo B and
    2. Lee AS
    : The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 32(7): 805-818, 2013. PMID: 22508478. DOI: 10.1038/onc.2012.130
    OpenUrlCrossRef
  34. ↵
    1. Bailly C and
    2. Waring MJ
    : Pharmacological effectors of GRP78 chaperone in cancers. Biochem Pharmacol 163: 269-278, 2019. PMID: 30831072. DOI: 10.1016/j.bcp.2019.02.038
    OpenUrlCrossRefPubMed
  35. ↵
    1. Freshney RI
    : Cell lines, culture of animal cells: a manual of basic technique. New York: Wiley-Liss; pp. 177-194, 2000.
  36. ↵
    1. Melikoğlu G,
    2. Bitiş L and
    3. Meriçli AH
    : Flavonoids of Crataegus microphylla. Nat Prod Res 18(3): 211-3, 2004. PMID: 15143829. DOI: 10.1080/14786410310001620673
    OpenUrlCrossRefPubMed
  37. ↵
    1. Kurashige S,
    2. Akuzawa Y and
    3. Endo F
    : Effects of astragali radix extract on carcinogenesis, cytokine production, and cytotoxicity in mice treated with a carcinogen, N-butyl-N’-butanolnitrosoamine. Cancer Invest 17(1): 30-35, 1999. PMID: 10999046. DOI: 10.1080/07357909909011714
    OpenUrlCrossRefPubMed
  38. ↵
    1. Betancur-Galvis L,
    2. Saez J,
    3. Granados H,
    4. Salazar A and
    5. Ossa J
    : Antitumor and antiviral activity of Colombian medicinal plant extracts. Mem Inst Oswaldo Cruz 94(4): 531-535, 1999. PMID: 10446015. DOI: 10.1590/s0074-02761999000400019
    OpenUrlCrossRefPubMed
  39. ↵
    1. Mosmann T
    : Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2): 55-63, 1983. PMID: 6606682. DOI: 10.1016/0022-1759(83)90303-4
    OpenUrlCrossRefPubMed
  40. ↵
    1. Ozturk M,
    2. Ozsoylemez OD and
    3. Dagistanli FK
    : The detection techniques for autophagy-associated cell death-related genes and proteins: Gene expression assay and immunohistochemistry. Methods Mol Biol 1854: 119-130, 2019. PMID: 28889353. DOI: 10.1007/7651_2017_67
    OpenUrlCrossRefPubMed
  41. ↵
    1. Idikio HA
    : Galectin-3 and Beclin1/Atg6 genes in human cancers: using cDNA tissue panel, qRT-PCR, and logistic regression model to identify cancer cell biomarkers. PLoS One 6(10): e26150, 2011. PMID: 22039439. DOI: 10.1371/journal.pone.0026150
    OpenUrlCrossRefPubMed
  42. ↵
    1. Schmittgen TD and
    2. Livak KJ
    : Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6): 1101-1108, 2008. PMID: 18546601. DOI: 10.1038/nprot.2008.73
    OpenUrlCrossRefPubMed
  43. ↵
    1. Chandrasekaran S,
    2. Cokol-Cakmak M,
    3. Sahin N,
    4. Yilancioglu K,
    5. Kazan H,
    6. Collins JJ and
    7. Cokol M
    : Chemogenomics and orthology-based design of antibiotic combination therapies. Mol Syst Biol 12(5): 872, 2016. PMID: 27222539. DOI: 10.15252/msb.20156777
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Yadav B,
    2. Wennerberg K,
    3. Aittokallio T and
    4. Tang J
    : Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J 13: 504-513, 2015. PMID: 26949479. DOI: 10.1016/j.csbj.2015.09.001
    OpenUrlCrossRefPubMed
  45. ↵
    1. Maiti P,
    2. Scott J,
    3. Sengupta D,
    4. Al-Gharaibeh A and
    5. Dunbar GL
    : Curcumin and solid lipid curcumin particles induce autophagy, but inhibit mitophagy and the PI3K-Akt/mTOR pathway in cultured glioblastoma cells. Int J Mol Sci 20(2): 399, 2019. PMID: 30669284. DOI: 10.3390/ijms20020399
    OpenUrlCrossRefPubMed
  46. ↵
    1. Xu Y,
    2. Xin Y,
    3. Diao Y,
    4. Lu C,
    5. Fu J,
    6. Luo L and
    7. Yin Z
    : Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS One 6(12): e29169, 2011. PMID: 22216199. DOI: 10.1371/journal.pone.0029169
    OpenUrlCrossRefPubMed
  47. ↵
    1. Mortezaee K,
    2. Salehi E,
    3. Mirtavoos-Mahyari H,
    4. Motevaseli E,
    5. Najafi M,
    6. Farhood B,
    7. Rosengren RJ and
    8. Sahebkar A
    : Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. J Cell Physiol 234(8): 12537-12550, 2019. PMID: 30623450. DOI: 10.1002/jcp.28122
    OpenUrlCrossRefPubMed
  48. ↵
    1. Zhang X,
    2. Wang R,
    3. Chen G,
    4. Dejean L and
    5. Chen QH
    : The Effects of Curcumin-based Compounds on Proliferation and Cell Death in Cervical Cancer Cells. Anticancer Res 35(10): 5293-5298, 2015. PMID: 26408689
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Kan PC,
    2. Chang YJ,
    3. Chien CS,
    4. Su CY and
    5. Fang HW
    : Coupling dichloroacetate treatment with curcumin significantly enhances anticancer potential. Anticancer Res 38(11): 6253-6261, 2018. PMID: 30396945. DOI: 10.21873/anticanres.12981
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Kayacan S,
    2. Yilancioglu K,
    3. Akdemir AS,
    4. Dagistanli FK,
    5. Melikoglu G and
    6. Ozturk M
    : The effects of apigenin and curcumin on autophagy related cell death and apoptosis. Proceedings 2: 1586, 2018. DOI:10.3390/proceedings2251586
    OpenUrlCrossRef
  51. ↵
    1. Lee JH,
    2. Yoon YM and
    3. Lee SH
    : GRP78 regulates apoptosis, cell survival and proliferation in 5-fluorouracil-resistant SNUC5 colon cancer cells. Anticancer Res 37(9): 4943-4951, 2017. PMID: 28870916. DOI: 10.21873/anticanres.11904
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Goldar S,
    2. Khaniani MS,
    3. Derakhshan SM and
    4. Baradaran B
    : Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 16(6): 2129-2144, 2015. PMID: 25824729. DOI: 10.7314/apjcp.2015.16.6.2129
    OpenUrlCrossRefPubMed
  53. ↵
    1. Liu G,
    2. Zou H,
    3. Luo T,
    4. Long M,
    5. Bian J,
    6. Liu X,
    7. Gu J,
    8. Yuan Y,
    9. Song R,
    10. Wang Y,
    11. Zhu J and
    12. Liu Z
    : Caspase-dependent and caspase-independent pathways are involved in cadmium-induced apoptosis in primary rat proximal tubular cell culture. PLoS One 11(11): e0166823, 2016. PMID: 27861627. DOI: 10.1371/journal.pone.0166823
    OpenUrlCrossRefPubMed
  54. ↵
    1. Boudreau MW,
    2. Peh J and
    3. Hergenrother PJ
    : Procaspase-3 overexpression in cancer: A paradoxical observation with therapeutic potential. ACS Chem Biol 14(11): 2335-2348, 2019. PMID: 31260254. DOI: 10.1021/acschembio.9b00338
    OpenUrlCrossRefPubMed
  55. ↵
    1. Pu X,
    2. Storr SJ,
    3. Zhang Y,
    4. Rakha EA,
    5. Green AR,
    6. Ellis IO and
    7. Martin SG
    : Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. Apoptosis 22(3): 357-368, 2017. PMID: 27798717. DOI: 10.1007/s10495-016-1323-5
    OpenUrlCrossRefPubMed
  56. ↵
    1. Flanagan L,
    2. Meyer M,
    3. Fay J,
    4. Curry S,
    5. Bacon O,
    6. Duessmann H,
    7. John K,
    8. Boland KC,
    9. McNamara DA,
    10. Kay EW,
    11. Bantel H,
    12. Schulze-Bergkamen H and
    13. Prehn JH
    : Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach. Cell Death Dis 7: e2087, 2016. PMID: 26844701. DOI: 10.1038/cddis.2016.7
    OpenUrlCrossRefPubMed
  57. ↵
    1. Wang Y,
    2. Wen X,
    3. Zhang N,
    4. Wang L,
    5. Hao D,
    6. Jiang X and
    7. He G
    : Small-molecule compounds target paraptosis to improve cancer therapy. Biomed Pharmacother 118: 109203, 2019. PMID: 31306970. DOI: 10.1016/j.biopha.2019.109203
    OpenUrlCrossRefPubMed
  58. ↵
    1. Yoon MJ,
    2. Kim EH,
    3. Lim JH,
    4. Kwon TK and
    5. Choi KS
    : Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells. Free Radic Biol Med 48(5): 713-726, 2010. PMID: 20036734. DOI: 10.1016/j.freeradbiomed.2009.12.016
    OpenUrlCrossRefPubMed
  59. ↵
    1. Garrido-Armas M,
    2. Corona JC,
    3. Escobar ML,
    4. Torres L,
    5. Ordóñez-Romero F,
    6. Hernández-Hernández A and
    7. Arenas-Huertero F
    : Paraptosis in human glioblastoma cell line induced by curcumin. Toxicol In Vitro 51: 63-73, 2018. PMID: 29723631. DOI: 10.1016/j.tiv.2018.04.014
    OpenUrlCrossRefPubMed
  60. ↵
    1. Niedzwiecki A,
    2. Roomi MW,
    3. Kalinovsky T and
    4. Rath M
    : Anticancer efficacy of polyphenols and their combinations. Nutrients 8(9): 2016. PMID: 27618095. DOI: 10.3390/nu8090552
    OpenUrlCrossRef
  61. ↵
    1. Wang L,
    2. Du F and
    3. Wang X
    : TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133(4): 693-703, 2008. PMID: 18485876. DOI: 10.1016/j.cell.2008.03.036
    OpenUrlCrossRefPubMed
  62. ↵
    1. Zambrano J and
    2. Yeh ES
    : Autophagy and apoptotic crosstalk: Mechanism of therapeutic resistance in HER2-positive breast cancer. Breast Cancer (Auckl) 10: 13-23, 2016. PMID: 26997868. DOI: 10.4137/BCBCR.S32791
    OpenUrlCrossRefPubMed
  63. ↵
    1. Gaballah HH,
    2. Gaber RA and
    3. Mohamed DA
    : Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms. Toxicol Appl Pharmacol 316: 27-35, 2017. PMID: 28025107. DOI: 10.1016/j.taap.2016.12.012
    OpenUrlCrossRefPubMed
  64. ↵
    1. Takahashi Y,
    2. Coppola D,
    3. Matsushita N,
    4. Cualing HD,
    5. Sun M,
    6. Sato Y,
    7. Liang C,
    8. Jung JU,
    9. Cheng JQ,
    10. Mulé JJ,
    11. Pledger WJ and
    12. Wang HG
    : Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 9(10): 1142-1151, 2007. PMID: 17891140. DOI: 10.1038/ncb1634
    OpenUrlCrossRefPubMed
    1. Park SE,
    2. Yi HJ,
    3. Suh N,
    4. Park YY,
    5. Koh JY,
    6. Jeong SY,
    7. Cho DH,
    8. Kim CS and
    9. Hwang JJ
    : Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB. Oncotarget 7(26): 39796-39808, 2016. PMID: 27174920. DOI: 10.18632/oncotarget.9290
    OpenUrlCrossRefPubMed
  65. ↵
    1. Lin Y,
    2. Hupp TR and
    3. Stevens C
    : Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death. FEBS J 277(1): 48-57, 2010. PMID: 19878313. DOI: 10.1111/j.1742-4658.2009.07411.x
    OpenUrlCrossRefPubMed
    1. Ozsoylemez OD,
    2. Ozturk M,
    3. Sutlupinar N,
    4. Kayacan S,
    5. Tuncdemir M and
    6. Ozan G
    : The effects of colchicum baytopiorum on regulatory genes of apoptotic and autophagic cell death in hela cells. Curr Pharm Biotechnol 17(15): 1369-1376, 2016. PMID: 27834133. DOI: 10.2174/1389201018666161109113543
    OpenUrlCrossRefPubMed
  66. ↵
    1. Zhou F,
    2. Yang Y and
    3. Xing D
    : Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 278(3): 403-413, 2011. PMID: 21182587. DOI: 10.1111/j.1742-4658.2010.07965.x
    OpenUrlCrossRefPubMed
  67. ↵
    1. Gordy C and
    2. He YW
    : The crosstalk between autophagy and apoptosis: Where does this lead? Protein Cell 3: 17-27, 2012. Doi: 10.1007/s13238-011-1127-x
    OpenUrlCrossRefPubMed
  68. ↵
    1. Kim SY,
    2. Song X,
    3. Zhang L,
    4. Bartlett DL and
    5. Lee YJ
    : Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. Biochem Pharmacol 88(2): 178-188, 2014. PMID: 24486574. DOI: 10.1016/j.bcp.2014.01.027
    OpenUrlCrossRefPubMed
  69. ↵
    1. Wirawan E,
    2. Vande Walle L,
    3. Kersse K,
    4. Cornelis S,
    5. Claerhout S,
    6. Vanoverberghe I,
    7. Roelandt R,
    8. De Rycke R,
    9. Verspurten J,
    10. Declercq W,
    11. Agostinis P,
    12. Vanden Berghe T,
    13. Lippens S and
    14. Vandenabeele P
    : Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 1: e18, 2010. PMID: 21364619. DOI: 10.1038/cddis.2009.16
    OpenUrlCrossRefPubMed
  70. ↵
    1. Lee H and
    2. Paik SG
    : Regulation of BNIP3 in normal and cancer cells. Mol Cells 21(1): 1-6, 2006. PMID: 16511341.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Kang R,
    2. Zeh HJ,
    3. Lotze MT and
    4. Tang D
    : The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 18(4): 571-580, 2011. PMID: 21311563. DOI: 10.1038/cdd.2010.191
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (3)
Anticancer Research
Vol. 41, Issue 3
March 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells
SERA KAYACAN, KAAN YILANCIOGLU, AYSE SEDA AKDEMIR, FATMA KAYA-DAGISTANLI, GULAY MELIKOGLU, MELEK OZTURK
Anticancer Research Mar 2021, 41 (3) 1271-1282; DOI: 10.21873/anticanres.14884

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Synergistic Effect of Apigenin and Curcumin on Apoptosis, Paraptosis and Autophagy-related Cell Death in HeLa Cells
SERA KAYACAN, KAAN YILANCIOGLU, AYSE SEDA AKDEMIR, FATMA KAYA-DAGISTANLI, GULAY MELIKOGLU, MELEK OZTURK
Anticancer Research Mar 2021, 41 (3) 1271-1282; DOI: 10.21873/anticanres.14884
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Apigenin-induced Apoptosis in Lung Adenocarcinoma A549 Cells: Involvement in IFNA2, TNF, and SPON2 With Different Time Points
  • Macranthoside B Enhances Paclitaxel-induced Human Cervical Cancer Cell Apoptosis Through ROS-JNK Pathway
  • Google Scholar

More in this TOC Section

  • ITGAV Regulation of LGALS3BP-JUNB Axis Facilitates the Cell-to-Cell Adhesion and Invasiveness of Hepatic Cancer Cells
  • High Antitumor Effects and Reduced Side Effects of Doxorubicin Prodrug Active Only Under Hypoxic Conditions
  • Apigenin-induced Apoptosis in Lung Adenocarcinoma A549 Cells: Involvement in IFNA2, TNF, and SPON2 With Different Time Points
Show more Experimental Studies

Similar Articles

Keywords

  • curcumin
  • Apigenin
  • synergy
  • autophagic cell death
  • apoptosis
  • paraptosis
  • GRP78
  • HeLa cell
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire